[1]Siegel RL，Miller KD，Jemal A.Cancer statistics，2015［J］.CA Cancer J Clin，2015，65(1)：5-29.
[2]Wu GM，Qian GS.Research on the resistance mechanism of advanced non-small cell lung cancer EGFR-TKIs treatment-a new light in the challenge［J］.Journal of the Third Military Medical University，2012，34(20)：2031-2034.［吴国明，钱桂生.晚期非小细胞肺癌EGFR-TKIs治疗的耐药机制研究—挑战中蕴含新的曙光［J］.第三军医大学学报，2012，34(20)：2031-2034.］
[3]Li P，Wang L，Jia LC.Research situation of the third generation epidermal growth factor receptor inhibitor，osimertinib［J］.Chin J Clin Pharmacol，2017，33(14)：1371-1373.［李萍，王丽，贾乐川.第3代表皮生长因子受体抑制药-奥西替尼研究状况［J］.中国临床药理学杂志，2017，33(14)：1371-1373.］
[4]Stephens RJ，Hopwood P，Girling DJ.Defining and analyzing symptom palliation in cancer clinical trials：A deceptively difficult exercise［J］.Br J Cancer，1999，79(324)：538-544.
[5]Herbst RS，O'Neill VJ，Fehrenbacher L，et al.Phase Ⅱ study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer［J］.J Clin Oncol，2007，25(30)：4743.
[6]Herbst RS，Ansari R，Bustin F，et al.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced nonsmall-cell lung cancer after failure of standard first-line chemotherapy（BeTa)：A double-blind，placebo-controlled，phase 3 trial［J］.Lancet，2011，377(9780)：1846.
[7]Naumov GN，Nilsson MB，Cascone T，et al.Combined vascular endothelial growth factor receptor and epidermal growth factor receptor（EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistaice［J］.Clin Cancer Res，2009，15(10)：3484.
[8]Wang HJ,Zhang GW,Wang QM,et al.Clinical study on the relief treatment of the combined recombinant human endostatin after failed treatment of gefitinib for advanced non-small cell lung cancer［J］.J Clin Med Prac，2012，16(21)：16-18.［王慧娟，张国伟，王启鸣，等.吉非替尼耐药的晚期非小细胞肺癌联合重组人血管内皮抑素解救治疗的临床研究［J］.实用临床医药杂志，2012，16（21）：16-18.］
[9]Ao X，Zhou TJ，Jiang M，et al.Analysis of the curative effects of DP，gefitinib combined with endostar in the treatment of non-small cell lung cancer［J］.Tumor Pharmacology，2017，7(03)：350-354.［敖翔，周天骏，姜明，等.DP、吉非替尼联合恩度治疗非小细胞肺癌的疗效分析［J］.肿瘤药学，2017，7(03)：350-354.］
[10]Wang JW，Sun Y,Liu YY，et al.Human recombinant vascular endothelial inhibition combined with NP regimen for advanced NSCLC randomized，double-blind，controlled，multicenter phase Ⅲ clinical research［J］.Chinese Journal of Lung Cancer，2005，8(4)：283-290.［王金万，孙燕，刘永煜，等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究［J］.中国肺癌杂志，2005，8(4)：283-290.］
[11]Wang JW，Sun Y，Qin SK，et al.Results of phase Ⅳ clinical trial of endostar with chemotherapy for treatment of（NSCLC)［J］.J Clin Oncol,2010，28(15 Suppl)：a7598.
[12]Rong B，Yang S，Li W，et al.Systematic review and meta-analysisof endostar（rh-endostatin)combined with chemotherapy versuschemotherapy alone for treating advanced non-small cell lung cancer［J］.World J Surg Oncol，2012，10：170.
[13]Alice G，Folkman J.Prediction that broader spectrum antiangio genic drugs,lowerdoses，continuing doses will improve outcomes［J］.Oncol Times，2007，29(2)：38-39.
[14]Hansma AH，Broxterman HJ，Van Der Horst I，et al.Recombinant human endostatin administered as a 28-day continuous infusion，followed by daily subcutaneous injections：A phase I and pharmacokinetic study in patients with advanced cancer［J］.Ann Oncol，2005，16(10)：1695-1701.
[15]Zhou Q，Hu JW，Yin R，et al.Clinical observation of recombinant human endostatin durative transfusion combined with window period chemotherapy in advanced non-small cell lung cancer［J］.Journal of Clinical Oncology，2014，19(12)：1113-1117.［周青，胡静雯，尹荣，等.重组人血管内皮抑素静脉泵入联合窗口期化疗治疗晚期非小细胞肺癌的临床观察［J］.临床肿瘤学杂志，2014，19(12)：1113-1117.］
[16]Zhi XY，Shi YK，Yu JM.Diagnosis and treatment of primary lung cancer in China（2015 edition)［J］.Chinese Journal of Oncology，2015，37(1)：67-78.［支修益，石远凯，于金明.中国原发性肺癌诊疗规范(2015年版)［J］.中华肿瘤杂志，2015，37(1)：67-78.］